Ibutamoren (MK-677): Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •4 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (5 countries listed)
Risk Assessment
Clinical trial in elderly hip fracture patients identified increased congestive heart failure rates with ibutamoren (6.5% vs 1.7% placebo), leading to early trial termination. Risk is likely mediated by GH-induced fluid retention in patients with underlying cardiac vulnerability.
MK-677 increases fasting glucose, reduces insulin sensitivity, and elevates HbA1c. These effects are particularly concerning in elderly, obese, or prediabetic populations and may increase risk of developing type 2 diabetes with long-term use.
Sustained IGF-1 elevation has been epidemiologically associated with increased risk of breast, prostate, and colorectal cancers. While no clinical trial of MK-677 demonstrated increased cancer incidence, studies were too small and short to adequately assess this risk.
MK-677 has never been approved by any regulatory agency. Products sold online as MK-677 are unregulated, may be mislabeled, contaminated, or counterfeit, and their purity and dosing accuracy cannot be verified.
⚠️Important Warnings
- •NOT APPROVED FOR HUMAN USE: Ibutamoren has never been approved by any regulatory agency worldwide. It remains an investigational compound.
- •HEART FAILURE RISK: A clinical trial in elderly patients was terminated early due to increased congestive heart failure rates. Patients with cardiac risk factors may be at particular danger.
- •WADA PROHIBITED: Classified as a prohibited substance (S2 category) by the World Anti-Doping Agency. Athletes may face sanctions for use or detection.
- •METABOLIC EFFECTS: Increases fasting blood glucose and reduces insulin sensitivity. May accelerate development of type 2 diabetes in at-risk individuals.
- •UNREGULATED PRODUCTS: Products sold as MK-677 through online vendors are unregulated and may contain incorrect doses, contaminants, or entirely different substances.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | Investigational New Drug (IND) that has never received FDA approval. Not legal as a dietary supplement ingredient. The FDA has issued warning letters to companies selling MK-677 as a supplement. Classified as a prohibited substance by WADA. |
| United Kingdom | Unregulated | Not approved for medical use. Classified as a selective androgen receptor modulator (SARM) or related compound under various regulatory frameworks. Available through research chemical vendors but not for human consumption. |
| European Union | Investigational | Not approved by EMA for any indication. Regulatory status varies by member state. Generally classified as an unapproved pharmaceutical substance. |
| Australia | Prohibited | Listed as a prohibited substance by the Australian Sports Anti-Doping Authority (ASADA) and Therapeutic Goods Administration (TGA). Not approved for human use. |
| Canada | Investigational | Not approved by Health Canada. Not legal as a natural health product or dietary supplement ingredient. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 300+ community reports
View community protocolsCritical Safety Information#
Ibutamoren (MK-677) is an unapproved investigational compound that has never received regulatory approval from any agency worldwide. Clinical development was effectively discontinued due to safety concerns, particularly increased rates of congestive heart failure in elderly populations. This page provides a comprehensive overview of known risks identified through clinical trials and the regulatory status of this compound.
Cardiovascular Risk#
Heart Failure Signal#
The most significant safety concern with ibutamoren is the increased rate of congestive heart failure identified in the Adunsky et al. hip fracture recovery trial:
- Ibutamoren group: 4 of 62 patients (6.5%) developed CHF
- Placebo group: 1 of 61 patients (1.7%) developed CHF
- Trial action: Terminated early due to this safety signal
The mechanism is thought to involve GH-mediated sodium and water retention in patients with subclinical cardiac dysfunction. Growth hormone therapy is known to cause fluid retention, and elderly patients recovering from hip fractures represent a population with high prevalence of underlying cardiovascular disease.
While the earlier Bach et al. (2004) trial in a similar population did not identify a CHF signal, the smaller sample size may have been insufficient to detect it.
Metabolic Risks#
Glucose Metabolism#
MK-677 adversely affects glucose metabolism through GH-mediated mechanisms:
- Fasting blood glucose increased by approximately 0.3 mmol/L (5 mg/dL)
- Insulin sensitivity declined
- HbA1c increased modestly
These effects are consistent with the known diabetogenic properties of GH excess and raise concerns about long-term metabolic consequences, particularly in populations already at risk for type 2 diabetes.
Cancer Considerations#
Elevated IGF-1 has been associated in epidemiologic studies with increased risk of certain malignancies. While MK-677 clinical trials were too small and short to assess cancer risk, the theoretical concern remains relevant for any therapy that chronically elevates IGF-1 levels.
Regulatory and Legal Status#
Not Approved for Human Use#
Ibutamoren has never been approved by the FDA, EMA, MHRA, Health Canada, TGA, or any other regulatory agency for any indication. It remains classified as an investigational new drug.
WADA Prohibited Substance#
The World Anti-Doping Agency prohibits ibutamoren under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Athletes testing positive for MK-677 face sanctions.
FDA Enforcement#
The FDA has issued warning letters to companies marketing MK-677 as a dietary supplement, stating it does not qualify as a dietary ingredient and that selling it for human consumption is illegal.
Unregulated Product Risks#
Products marketed as MK-677 through online vendors, research chemical suppliers, and supplement companies are completely unregulated. Specific risks include:
- Mislabeling: Products may contain different doses than stated
- Contamination: No GMP manufacturing requirements for research chemicals
- Adulteration: Products may contain different active ingredients entirely
- No quality assurance: Purity, sterility, and composition are unverified
Risk Mitigation#
Given its unapproved status, the primary risk mitigation for ibutamoren is to recognize that it is not a legitimate therapeutic option. For clinicians and researchers:
- Clinical development was discontinued due to identified cardiovascular risks
- No approved therapeutic indication exists
- Alternative FDA-approved GH therapies (tesamorelin, somatropin) are available for appropriate indications
- The risk-benefit profile does not support use outside of regulated clinical trials
Related Reading#
Frequently Asked Questions About Ibutamoren (MK-677)
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.